BridgeBio Pharma Inc
BBIO47.670USD
+0.300+0.63%
Horário de mercado （ET）Cotações atrasadas em 15 min
9.05BValor de mercado
PerdaP/L TTM
Mais detalhes de BridgeBio Pharma Inc Empresa
BridgeBio Pharma, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on discovering, creating, testing and delivering transformative medicines to treat patients who suffer from genetic diseases and cancers with clear genetic drivers. The Company's pipeline of development programs ranges from early science to advanced clinical trials that include Acoramidis (AG10), a next-generation small molecule near-complete transthyretin (TTR) stabilizer, for the treatment of amyloidosis TTR (ATTR); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor (TKI), as a treatment option for children with achondroplasia; Encaleret, a small molecule antagonist of the calcium sensing receptor (CaSR) for the treatment of Autosomal Dominant Hypocalcemia Type 1 (ADH1), and BBP-418, an investigational, orally administered, small molecule substrate supplementation therapy that the Company is developing for the treatment of LGMD2I, also known as LGMDR9.
Informações da empresa
Código da empresaBBIO
Nome da EmpresaBridgeBio Pharma Inc
Data de listagemJun 27, 2019
CEODr. Neil Kumar, Ph.D.
Número de funcionários725
Tipo de títulosOrdinary Share
Fim do ano fiscalJun 27
Endereço3160 Porter Dr.
CidadePALO ALTO
Bolsa de valoresNASDAQ Global Select Consolidated
PaísUnited States of America
Código postal94304
Telefone16503919740
Sitehttps://bridgebio.com/
Código da empresaBBIO
Data de listagemJun 27, 2019
CEODr. Neil Kumar, Ph.D.
Executivos da empresa
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Neil Kumar, Ph.D.
Dr. Neil Kumar, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
6.16M
+0.09%
Dr. Charles J. Homcy, M.D.
Dr. Charles J. Homcy, M.D.
Lead Director, Chairman of Pharmaceuticals
Lead Director, Chairman of Pharmaceuticals
1.22M
-1.09%
Mr. Ali J. Satvat
Mr. Ali J. Satvat
Independent Director
Independent Director
165.99K
+4.13%
Mr. James C. (Jim) Momtazee
Mr. James C. (Jim) Momtazee
Independent Director
Independent Director
95.08K
+7.45%
Dr. Thomas Trimarchi, Ph.D.
Dr. Thomas Trimarchi, Ph.D.
President, Chief Financial Officer
President, Chief Financial Officer
57.85K
-26.92%
Mr. Fred Hassan
Mr. Fred Hassan
Lead Independent Director
Lead Independent Director
25.89K
+34.14%
Mr. Ronald J. Daniels, J.D.
Mr. Ronald J. Daniels, J.D.
Independent Director
Independent Director
16.99K
+63.34%
Dr. Randal W. (Randy) Scott, Ph.D.
Dr. Randal W. (Randy) Scott, Ph.D.
Independent Director
Independent Director
15.59K
+73.21%
Ms. Jennifer E. Cook
Ms. Jennifer E. Cook
Independent Director
Independent Director
13.74K
+92.13%
Dr. Eric Aguiar, M.D.
Dr. Eric Aguiar, M.D.
Independent Director
Independent Director
6.59K
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Neil Kumar, Ph.D.
Dr. Neil Kumar, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
6.16M
+0.09%
Dr. Charles J. Homcy, M.D.
Dr. Charles J. Homcy, M.D.
Lead Director, Chairman of Pharmaceuticals
Lead Director, Chairman of Pharmaceuticals
1.22M
-1.09%
Mr. Ali J. Satvat
Mr. Ali J. Satvat
Independent Director
Independent Director
165.99K
+4.13%
Mr. James C. (Jim) Momtazee
Mr. James C. (Jim) Momtazee
Independent Director
Independent Director
95.08K
+7.45%
Dr. Thomas Trimarchi, Ph.D.
Dr. Thomas Trimarchi, Ph.D.
President, Chief Financial Officer
President, Chief Financial Officer
57.85K
-26.92%
Mr. Fred Hassan
Mr. Fred Hassan
Lead Independent Director
Lead Independent Director
25.89K
+34.14%
Detalhamento da receita
Moeda: USDAtualizado em: dom, 6 de jul
Moeda: USDAtualizado em: dom, 6 de jul
FY2025Q1
FY2024
FY2023
FY2022
FY2021
FY2020
FY2019
Sem dados
Por RegiãoUSD
Nome
Receita
Proporção
Europe Middle East and Africa (EMEA)
77.09M
66.10%
United States
36.86M
31.60%
Asia Pacific (APAC)
2.68M
2.30%
Por Empresa
Por Região
Sem dados
Distribuição de ações
Atualizado em: sex, 16 de mai
Atualizado em: sex, 16 de mai
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
Viking Global Investors LP
9.80%
The Vanguard Group, Inc.
8.68%
Kohlberg Kravis Roberts & Co. L.P.
6.98%
BlackRock Institutional Trust Company, N.A.
5.89%
Janus Henderson Investors
3.78%
Other
64.87%
Investidores
Investidores
Proporção
Viking Global Investors LP
9.80%
The Vanguard Group, Inc.
8.68%
Kohlberg Kravis Roberts & Co. L.P.
6.98%
BlackRock Institutional Trust Company, N.A.
5.89%
Janus Henderson Investors
3.78%
Other
64.87%
Tipos de investidores
Investidores
Proporção
Investment Advisor
32.61%
Investment Advisor/Hedge Fund
31.42%
Hedge Fund
15.71%
Private Equity
8.99%
Individual Investor
4.95%
Research Firm
3.23%
Venture Capital
1.89%
Sovereign Wealth Fund
0.56%
Bank and Trust
0.49%
Other
0.16%
Participação acionária institucional
Atualizado em: ter, 1 de jul
Atualizado em: ter, 1 de jul
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q2
620
190.27M
100.20%
-5.13M
2025Q1
628
200.01M
105.33%
-2.20M
2024Q4
586
190.11M
100.07%
-10.58M
2024Q3
566
185.43M
98.60%
-19.02M
2024Q2
541
188.12M
100.51%
-8.17M
2024Q1
529
185.29M
101.24%
-2.60M
2023Q4
525
179.04M
102.35%
-7.24M
2023Q3
519
174.99M
102.35%
-1.47M
2023Q2
503
162.75M
101.40%
-17.06M
2023Q1
513
164.96M
102.84%
-5.53M
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
Viking Global Investors LP
18.56M
9.77%
-3.50M
-15.87%
Jun 27, 2025
The Vanguard Group, Inc.
14.87M
7.83%
-177.77K
-1.18%
Mar 31, 2025
Kohlberg Kravis Roberts & Co. L.P.
13.26M
6.98%
-6.00M
-31.15%
May 12, 2025
BlackRock Institutional Trust Company, N.A.
11.18M
5.89%
-318.26K
-2.77%
Mar 31, 2025
Janus Henderson Investors
7.17M
3.78%
+2.26M
+46.13%
Mar 31, 2025
Kumar (Neil)
6.16M
3.25%
+5.69K
+0.09%
May 19, 2025
Aisling Capital Management LP
6.07M
3.2%
--
--
Mar 31, 2025
State Street Global Advisors (US)
5.75M
3.03%
-433.01K
-7.00%
Mar 31, 2025
Farallon Capital Management, L.L.C.
5.73M
3.02%
+1.54M
+36.62%
Mar 31, 2025
Capital Research Global Investors
4.67M
2.46%
+1.14M
+32.34%
Mar 31, 2025
Ver Mais
ETFs Relacionados
Atualizado em: sáb, 2 de ago
Atualizado em: sáb, 2 de ago
Nome
Proporção
Tema Oncology ETF
4.11%
Tema Heart & Health ETF
3.19%
Franklin Genomic Advancements ETF
2.39%
SPDR S&P Biotech ETF
2.15%
Virtus LifeSci Biotech Products ETF
2.1%
Direxion Daily S&P Biotech Bull 3X Shares
1.23%
Invesco Nasdaq Biotechnology ETF
0.91%
ProShares Ultra Nasdaq Biotechnology
0.91%
First Trust Mid Cap Growth AlphaDEX Fund
0.83%
iShares Health Innovation Active ETF
0.8%
Ver Mais
Tema Oncology ETF
Proporção4.11%
Tema Heart & Health ETF
Proporção3.19%
Franklin Genomic Advancements ETF
Proporção2.39%
SPDR S&P Biotech ETF
Proporção2.15%
Virtus LifeSci Biotech Products ETF
Proporção2.1%
Direxion Daily S&P Biotech Bull 3X Shares
Proporção1.23%
Invesco Nasdaq Biotechnology ETF
Proporção0.91%
ProShares Ultra Nasdaq Biotechnology
Proporção0.91%
First Trust Mid Cap Growth AlphaDEX Fund
Proporção0.83%
iShares Health Innovation Active ETF
Proporção0.8%
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Tipo
Proporção
Sem dados
Data
Tipo
Proporção
Sem dados
